Phase III study of monotherapy by gemcitabine or vinorelbine comparing to doublet by carboplatin and paclitaxel among elderly patients with stage IIIB/IV NSCLC (obligatory second-line by erlotinib).

Trial Profile

Phase III study of monotherapy by gemcitabine or vinorelbine comparing to doublet by carboplatin and paclitaxel among elderly patients with stage IIIB/IV NSCLC (obligatory second-line by erlotinib).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Carboplatin (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary) ; Gemcitabine; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2012 Results reporting outcomes for second-line erlotinib presented at the 37th Congress of the European Society for Medical Oncology.
    • 08 Aug 2011 Primary endpoint 'Overall-survival' has been met.
    • 08 Aug 2011 Results after 30.3 months of follow-up published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top